Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era

References

• Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–260.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118:4166–4172.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Sehn LH, et al. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96:1002–1007.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23:2797–2804.
   PubMed Web of Science ®Google Scholar
• Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90:809–818.
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014;55:2228–2240.
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21:1046–1052.
   PubMed Web of Science ®Google Scholar
• Pohlen M, Gerth HU, Liersch R, et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. Am J Hematol. 2011;86:E61–E64.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Richards MA, Mootoosamy I, Reznek RH, et al. Renal involvement in patients with non-Hodgkin's lymphoma: clinical and pathological features in 23 cases. Hematol Oncol. 1990;8:105–110.
   PubMed Web of Science ®Google Scholar
• Geffen DB, Fisher RI, Longo DL Jr, et al., Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. J Clin Oncol. 1985;3:646–653.
   PubMed Web of Science ®Google Scholar
• Morel P, Dupriez B, Herbrecht R, et al. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des lymphomes de l'Adulte. Br J Cancer. 1994;70:154–159.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–533.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–1867.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127–4133.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013;8:e55870.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–4290.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol. 2007;18:149–157.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 – the southwest oncology group. J Clin Oncol. 2009;27:114–119.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera international trial and trials of the German high-grade non-Hodgkin lymphoma study group. Ann Oncol. 2012;23:1267–1273.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des lymphomes de l'Adulte. Ann Oncol. 2000;11:685–690.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol. 2013;31:Abstract 47.
   Google Scholar
• Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood. 2014;124:Abstract 394.
   Google Scholar
• Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55:509–514.
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15:129–133.
   PubMed Web of Science ®Google Scholar
• Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma. 2015;56:725–729.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Bruno-Ventre M, Donadoni G, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168:654–662.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep. 2015;17:25.
   PubMed Web of Science ®Google Scholar